Source: Medicines & Healthcare Products Regulatory Agency (GB) Revision Year: 2019 Publisher: Nordic Group B.V., Siriusdreef 22, 2132 WT Hoofddorp, The Netherlands
Mifegyne 200 mg tablets.
| Pharmaceutical Form |
|---|
|
Tablet. Light yellow, cylindrical, bi-convex tablets, with a diameter of 11 mm with “167 B” engraved on one side. |
Each tablet contains 200-mg mifepristone.
For the full list of excipients, see section 6.1.
| Active Ingredient | Description | |
|---|---|---|
| Mifepristone |
Mifepristone is a synthetic steroid with an antiprogestational action as a result of competition with progesterone at the progesterone receptors. |
| List of Excipients |
|---|
|
Silica, colloidal anhydrous (E551) |
PVC/aluminium perforated unit dose blister packs of 1, 3 × 1, 15 × 1 or 30 × 1 tablets.
Not all pack sizes may be marketed.
Nordic Group B.V., Siriusdreef 22, 2132 WT Hoofddorp, The Netherlands
PL 40621/0022
30/04/2017
| Drug | Countries | |
|---|---|---|
| MIFEGYNE | Austria, Cyprus, Estonia, Spain, Finland, France, Hong Kong, Croatia, Ireland, Israel, Netherlands, New Zealand, Romania, Singapore, Tunisia, United Kingdom, South Africa |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
